Bristol-Myers Squibb Co (NYSE:BMY) Holdings Trimmed by First Mercantile Trust Co.

Share on StockTwits

First Mercantile Trust Co. cut its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 79.5% during the 1st quarter, HoldingsChannel reports. The fund owned 15,435 shares of the biopharmaceutical company’s stock after selling 59,910 shares during the period. First Mercantile Trust Co.’s holdings in Bristol-Myers Squibb were worth $737,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc boosted its holdings in Bristol-Myers Squibb by 1.0% during the third quarter. Vanguard Group Inc now owns 128,376,159 shares of the biopharmaceutical company’s stock worth $7,969,593,000 after buying an additional 1,229,553 shares in the last quarter. KBC Group NV boosted its holdings in Bristol-Myers Squibb by 3.9% during the fourth quarter. KBC Group NV now owns 415,848 shares of the biopharmaceutical company’s stock worth $21,615,000 after buying an additional 15,465 shares in the last quarter. Signet Investment Advisory Group Inc. bought a new stake in Bristol-Myers Squibb during the fourth quarter worth approximately $161,000. Harvey Investment Co. LLC bought a new stake in Bristol-Myers Squibb during the fourth quarter worth approximately $323,000. Finally, Exane Derivatives boosted its holdings in Bristol-Myers Squibb by 475.0% during the fourth quarter. Exane Derivatives now owns 27,181 shares of the biopharmaceutical company’s stock worth $1,413,000 after buying an additional 22,454 shares in the last quarter. Institutional investors and hedge funds own 77.65% of the company’s stock.

In related news, Director Theodore R. Samuels II bought 5,000 shares of the business’s stock in a transaction on Thursday, May 16th. The stock was bought at an average price of $47.29 per share, for a total transaction of $236,450.00. Following the transaction, the director now directly owns 27,000 shares in the company, valued at $1,276,830. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Karen Murphy Santiago sold 3,065 shares of the stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $47.56, for a total transaction of $145,771.40. Following the completion of the sale, the insider now owns 3,066 shares of the company’s stock, valued at approximately $145,818.96. The disclosure for this sale can be found here. Company insiders own 0.12% of the company’s stock.

Bristol-Myers Squibb stock opened at $47.63 on Thursday. Bristol-Myers Squibb Co has a 52 week low of $44.30 and a 52 week high of $63.69. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.93 and a quick ratio of 1.79. The company has a market capitalization of $76.67 billion, a P/E ratio of 11.32, a PEG ratio of 2.19 and a beta of 0.74.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported $1.10 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.01. Bristol-Myers Squibb had a net margin of 22.23% and a return on equity of 48.72%. The firm had revenue of $5.92 billion during the quarter, compared to analyst estimates of $5.72 billion. During the same quarter last year, the business posted $0.94 EPS. The company’s revenue was up 14.0% on a year-over-year basis. Equities analysts forecast that Bristol-Myers Squibb Co will post 4.18 EPS for the current year.

A number of analysts recently weighed in on BMY shares. BMO Capital Markets raised their target price on shares of Bristol-Myers Squibb from $62.00 to $63.00 and gave the stock an “outperform” rating in a report on Wednesday, April 17th. Zacks Investment Research cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Friday, February 22nd. ValuEngine cut shares of Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a report on Thursday, April 4th. Goldman Sachs Group started coverage on shares of Bristol-Myers Squibb in a report on Tuesday, May 28th. They set a “buy” rating and a $54.00 target price for the company. Finally, Argus cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 target price for the company. in a report on Monday, May 20th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $56.69.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Macon Daily and is the sole property of of Macon Daily. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://macondaily.com/2019/06/13/bristol-myers-squibb-co-nysebmy-holdings-trimmed-by-first-mercantile-trust-co.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Read More: How Do Tariffs Affect Trade Balances?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.